HaLixun InternationalPeace Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Yan
CRAD-001-03, NCT05295173: A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Completed
3
1412
RoW
Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA
Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital
Acute Ischemic Stroke
06/23
06/23
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting
3
518
RoW
TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
08/25
12/25
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
12/25
12/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Yan
CRAD-001-03, NCT05295173: A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Completed
3
1412
RoW
Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA
Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital
Acute Ischemic Stroke
06/23
06/23
TQB2450-III-13, NCT06475599: Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not yet recruiting
3
420
RoW
Anlotinib hydrochloride capsule + TQB2450 injection, Chemotherapy drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endometrial Cancer
12/27
06/29
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting
3
518
RoW
TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-small Cell Lung Cancer
08/25
12/25
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
12/25
12/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
1123
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25

Download Options